Common Contracts
23 similar Underwriting Agreement contracts by Krystal Biotech, Inc., Eyenovia, Inc., Kadmon Holdings, Inc., others
Femasys Inc. [●] Shares Common Stock ($0.001 par value) Underwriting AgreementUnderwriting Agreement • June 14th, 2021 • Femasys Inc • Surgical & medical instruments & apparatus • New York
Femasys Inc., a corporation organized under the laws of Delaware (the “Issuer”), proposes to issue and sell to the several underwriters named in Schedule I hereto (the “Underwriters”), for whom Chardan Capital Markets LLC is acting as representative (the “Representative”), [●] shares of common stock, $0.001 par value per share (“Common Stock”) of the Issuer (said shares to be issued and sold by the Issuer being hereinafter called the “Underwritten Securities”). The Issuer also proposes to grant to the Underwriters an option to purchase up to [●] additional shares of Common Stock to cover over-allotments, if any (the “Option Securities;” the Option Securities, together with the Underwritten Securities, hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule I other than you, the term Representative as used herein shall mean you, as Underwriter, and the terms Representative and Underwriter shall mean either the singular or plural as the
Krystal Biotech, Inc. 1,923,077 Shares Common Stock ($0.00001 par value) Underwriting AgreementUnderwriting Agreement • February 5th, 2021 • Krystal Biotech, Inc. • Biological products, (no disgnostic substances) • New York
Krystal Biotech, Inc., a corporation organized under the laws of Delaware (the “Issuer”), proposes to issue and sell to the several underwriters named in Schedule I hereto (the “Underwriters”), for whom Goldman Sachs & Co. LLC (“Goldman Sachs”), Cowen and Company, LLC (“Cowen”) and Evercore Group L.L.C. (“Evercore”) are acting as representatives (the “Representatives”), 1,923,077 shares of common stock, $0.00001 par value per share (“Common Stock”) of the Issuer (said shares to be issued and sold by the Issuer being hereinafter called the “Underwritten Securities”). The Issuer also proposes to grant to the Underwriters an option to purchase 288,461 additional shares of Common Stock to cover over-allotments, if any (the “Option Securities;” the Option Securities, together with the Underwritten Securities, hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule I other than you, the term Representatives as used herein shall mean you, as
Immunome, Inc. [●] Shares Common Stock ($0.0001 par value) Underwriting AgreementUnderwriting Agreement • September 9th, 2020 • Immunome Inc. • Pharmaceutical preparations • New York
Immunome, Inc., a corporation organized under the laws of Delaware (the “Issuer”), proposes to issue and sell to the several underwriters named in Schedule I hereto (the “Underwriters”), for whom Ladenburg Thalmann & Co. Inc. and Chardan Capital Markets, LLC are acting as representatives (the “Representatives”), [●] shares of common stock, $0.0001 par value per share (“Common Stock”) of the Issuer (said shares to be issued and sold by the Issuer being hereinafter called the “Underwritten Securities”). The Issuer also proposes to grant to the Underwriters an option to purchase up to [●] additional shares of Common Stock to cover over-allotments, if any (the “Option Securities;” the Option Securities, together with the Underwritten Securities, hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule I other than you, the term Representative as used herein shall mean you, as Underwriter, and the terms Representatives and Underwriters shal
Eyenovia, Inc. 3,333,334 Shares Common Stock ($0.0001 par value) Underwriting AgreementUnderwriting Agreement • August 21st, 2020 • Eyenovia, Inc. • Pharmaceutical preparations • New York
Eyenovia, Inc., a corporation organized under the laws of Delaware (the “Issuer”), proposes to issue and sell to the several underwriters named in Schedule I hereto (the “Underwriters”), for whom William Blair & Company, L.L.C. is acting as representative (the “Representative”), 3,333,334 shares of common stock, $0.0001 par value per share (“Common Stock”) of the Issuer (said shares to be issued and sold by the Issuer being hereinafter called the “Underwritten Securities”). The Issuer also proposes to grant to the Underwriters an option to purchase up to 500,000 additional shares of Common Stock to cover over-allotments, if any (the “Option Securities;” the Option Securities, together with the Underwritten Securities, hereinafter called the “Securities”). The offering and sale of the Securities contemplated by this Agreement is referred to herein as the “Offering.”
Krystal Biotech, Inc. 2,275,000 Shares Common Stock ($0.00001 par value) Underwriting AgreementUnderwriting Agreement • May 21st, 2020 • Krystal Biotech, Inc. • Biological products, (no disgnostic substances) • New York
Krystal Biotech, Inc., a corporation organized under the laws of Delaware (the “Issuer”), proposes to issue and sell to the several underwriters named in Schedule I hereto (the “Underwriters”), for whom Cowen and Company, LLC (“Cowen”) and Evercore Group L.L.C. (“Evercore”) are acting as representatives (the “Representatives”), 2,275,000 shares of common stock, $0.00001 par value per share (“Common Stock”) of the Issuer (said shares to be issued and sold by the Issuer being hereinafter called the “Underwritten Securities”). The Issuer also proposes to grant to the Underwriters an option to purchase 341,250 additional shares of Common Stock to cover over-allotments, if any (the “Option Securities;” the Option Securities, together with the Underwritten Securities, hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule I other than you, the term Representatives as used herein shall mean you, as Underwriter, and the terms Representatives
EX-1.1 2 d669557dex11.htm EX-1.1 PhaseBio Pharmaceuticals, Inc. [•] Shares Common Stock ($0.001 par value) Underwriting Agreement New York, New York Citigroup Global Markets Inc. Cowen and Company, LLC Stifel, Nicolaus & Company, Incorporated As...Underwriting Agreement • May 5th, 2020 • New York
PhaseBio Pharmaceuticals, Inc., a corporation organized under the laws of Delaware (the “Issuer”), proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”), for whom Citigroup Global Markets Inc., Cowen and Company, LLC and Stifel, Nicolaus & Company, Incorporated (the “Representatives”) are acting as representatives, [•] shares of common stock, $0.001 par value per share(“Common Stock”) of the Issuer (said shares to be issued and sold by the Issuer being hereinafter called the “Underwritten Securities”). The Issuer also proposes to grant to the Underwriters an option to purchase up to [•] additional shares of Common Stock to cover over-allotments, if any (the “Option Securities;” the Option Securities, together with the Underwritten Securities, hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule I other than you, the term Representatives as used herein shall mean you, as Underwriters, and the t
26,000,000 Shares of Common Stock ($0.001 par value) Underwriting AgreementUnderwriting Agreement • November 14th, 2019 • Kadmon Holdings, Inc. • Pharmaceutical preparations • New York
Kadmon Holdings, Inc., a Delaware corporation (the “Issuer”), proposes to issue and sell to the several underwriters named in Schedule I hereto (the “Underwriters”), for whom Jefferies LLC (“Jefferies”) and Cantor Fitzgerald & Co. (“Cantor” and, together with Jefferies, the “Representatives”) are acting as representatives, 26,000,000 shares (the “Firm Shares”) of common stock, $0.001 par value (“Common Stock”), of the Issuer. The Issuer also proposes to grant to the Underwriters an option to purchase up to 3,900,000 additional shares of Common Stock (the “Option Shares” and together with the Firm Shares, the “Shares” or the “Securities”).
Eyenovia, Inc. 4,388,490 Shares Common Stock ($0.0001 par value) Underwriting AgreementUnderwriting Agreement • July 15th, 2019 • Eyenovia, Inc. • Pharmaceutical preparations • New York
Eyenovia, Inc., a corporation organized under the laws of Delaware (the “Issuer”), proposes to issue and sell to the several underwriters named in Schedule I hereto (the “Underwriters”), for whom Oppenheimer & Co. Inc. is acting as representative (the “Representative”), 4,388,490 shares of common stock, $0.0001 par value per share (“Common Stock”) of the Issuer (said shares to be issued and sold by the Issuer being hereinafter called the “Underwritten Securities”). The Issuer also proposes to grant to the Underwriters an option to purchase up to 658,273 additional shares of Common Stock to cover over-allotments, if any (the “Option Securities;” the Option Securities, together with the Underwritten Securities, hereinafter called the “Securities”). The offering and sale of the Securities contemplated by this Agreement is referred to herein as the “Offering.”
Krystal Biotech, Inc. 2,500,000 Shares Common Stock ($0.00001 par value) Underwriting AgreementUnderwriting Agreement • June 27th, 2019 • Krystal Biotech, Inc. • Biological products, (no disgnostic substances) • New York
Krystal Biotech, Inc., a corporation organized under the laws of Delaware (the “Issuer”), proposes to issue and sell to the several underwriters named in Schedule I hereto (the “Underwriters”), for whom Goldman Sachs & Co. LLC (“Goldman Sachs”) and Cowen and Company, LLC (“Cowen”) are acting as representatives (the “Representatives”), 2,500,000 shares of common stock, $0.00001 par value per share (“Common Stock”) of the Issuer (said shares to be issued and sold by the Issuer being hereinafter called the “Underwritten Securities”). The Issuer also proposes to grant to the Underwriters an option to purchase 375,000 additional shares of Common Stock to cover over-allotments, if any (the “Option Securities;” the Option Securities, together with the Underwritten Securities, hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule I other than you, the term Representatives as used herein shall mean you, as Underwriter, and the terms Represen
PhaseBio Pharmaceuticals, Inc. [ ] Shares Common Stock ($0.001 par value) Underwriting AgreementUnderwriting Agreement • April 9th, 2019 • PhaseBio Pharmaceuticals Inc • Pharmaceutical preparations • New York
PhaseBio Pharmaceuticals, Inc., a corporation organized under the laws of Delaware (the “Issuer”), proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”), for whom Citigroup Global Markets Inc., Cowen and Company, LLC and Stifel, Nicolaus & Company, Incorporated (the “Representatives”) are acting as representatives, [ ] shares of common stock, $0.001 par value per share (“Common Stock”) of the Issuer (said shares to be issued and sold by the Issuer being hereinafter called the “Underwritten Securities”). The Issuer also proposes to grant to the Underwriters an option to purchase up to [ ] additional shares of Common Stock to cover over-allotments, if any (the “Option Securities;” the Option Securities, together with the Underwritten Securities, hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule I other than you, the term Representatives as used herein shall mean you, as Underwriters, and the
Krystal Biotech, Inc. 3,000,000 Shares Common Stock ($0.00001 par value) Underwriting AgreementUnderwriting Agreement • October 19th, 2018 • Krystal Biotech, Inc. • Biological products, (no disgnostic substances) • New York
Krystal Biotech, Inc., a corporation organized under the laws of Delaware (the “Issuer”), proposes to issue and sell to the several underwriters named in Schedule I hereto (the “Underwriters”), for whom Cowen and Company, LLC (“Cowen”), William Blair & Company, L.L.C. (“William Blair”) and Cantor Fitzgerald & Co. are acting as representatives (the “Representatives”), 3,000,000 shares of common stock, $0.00001 par value per share (“Common Stock”) of the Issuer (said shares to be issued and sold by the Issuer being hereinafter called the “Underwritten Securities”). The Issuer also proposes to grant to the Underwriters an option to purchase 450,000 additional shares of Common Stock to cover over-allotments, if any (the “Option Securities;” the Option Securities, together with the Underwritten Securities, hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule I other than you, the term Representatives as used herein shall mean you, as Un
PhaseBio Pharmaceuticals, Inc. [•] Shares Common Stock ($0.001 par value) Underwriting AgreementUnderwriting Agreement • October 5th, 2018 • PhaseBio Pharmaceuticals Inc • Pharmaceutical preparations • New York
PhaseBio Pharmaceuticals, Inc., a corporation organized under the laws of Delaware (the “Issuer”), proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”), for whom Citigroup Global Markets Inc., Cowen and Company, LLC and Stifel, Nicolaus & Company, Incorporated (the “Representatives”) are acting as representatives, [•] shares of common stock, $0.001 par value per share(“Common Stock”) of the Issuer (said shares to be issued and sold by the Issuer being hereinafter called the “Underwritten Securities”). The Issuer also proposes to grant to the Underwriters an option to purchase up to [•] additional shares of Common Stock to cover over-allotments, if any (the “Option Securities;” the Option Securities, together with the Underwritten Securities, hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule I other than you, the term Representatives as used herein shall mean you, as Underwriters, and the t
Alzheon, Inc. [•] Shares Common Stock ($0.001 par value) Underwriting AgreementUnderwriting Agreement • September 28th, 2018 • Alzheon, Inc. • Pharmaceutical preparations • New York
Alzheon, Inc., a corporation organized under the laws of Delaware (the “Issuer”), proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”), for whom ThinkEquity, a division of Fordham Financial Management, Inc. (“ThinkEquity”) and H.C. Wainwright & Co., LLC are acting as representatives (collectively, the “Representatives”), [•] shares of common stock, $0.001 par value per share (“Common Stock”) of the Issuer (said shares to be issued and sold by the Issuer being hereinafter called the “Underwritten Securities”). The Issuer also proposes to grant to the Underwriters an option to purchase up to [•] additional shares of Common Stock to cover over-allotments, if any (the “Option Securities;” the Option Securities, together with the Underwritten Securities, hereinafter called the “Securities”). [The Issuer also proposes to issue to the Representatives (and/or their designees) on the Closing Date (as defined herein) warrants (collectively, the “Representa
Kadmon Holdings, Inc. 26,666,667 Shares of Common Stock ($0.001 par value) Underwriting AgreementUnderwriting Agreement • June 14th, 2018 • Kadmon Holdings, Inc. • Pharmaceutical preparations • New York
Kadmon Holdings, Inc., a Delaware corporation (the “Issuer”), proposes to issue and sell to the several underwriters named in Schedule I hereto (the “Underwriters”), for whom Jefferies LLC (“Jefferies” or the “Representative”) is acting as representative, 26,666,667 shares (the “Firm Shares”) of common stock, $0.001 par value (“Common Stock”), of the Issuer. The Issuer also proposes to grant to the Underwriters an option to purchase up to 4,000,000 additional shares of Common Stock (the “Option Shares” and together with the Firm Shares, the “Shares” or the “Securities”). To the extent there are no additional Underwriters listed on Schedule I other than you, the term Underwriters shall mean either the singular or plural as the context requires.
Alzheon, Inc. [•] Shares Common Stock ($0.001 par value) Underwriting AgreementUnderwriting Agreement • March 16th, 2018 • Alzheon, Inc. • Pharmaceutical preparations • New York
Alzheon, Inc., a corporation organized under the laws of Delaware (the “Issuer”), proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”), for whom Citigroup Global Markets Inc. and Piper Jaffray & Co. (the “Representatives”) are acting as representatives, [•] shares of common stock, $0.001 par value per share (“Common Stock”) of the Issuer (said shares to be issued and sold by the Issuer being hereinafter called the “Underwritten Securities”). The Issuer also proposes to grant to the Underwriters an option to purchase up to [•] additional shares of Common Stock to cover over-allotments, if any (the “Option Securities;” the Option Securities, together with the Underwritten Securities, hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule I other than you, the term Representatives as used herein shall mean you, as Underwriters, and the terms Representatives and Underwriters shall mean either the s
Eyenovia, Inc. 2,730,000 Shares Common Stock ($0.0001 par value) Underwriting AgreementUnderwriting Agreement • January 29th, 2018 • Eyenovia, Inc. • Pharmaceutical preparations • New York
Eyenovia, Inc., a corporation organized under the laws of Delaware (the “Issuer”), proposes to issue and sell to the several underwriters named in Schedule I hereto (the “Underwriters”), for whom Ladenburg Thalmann & Co. Inc. and Roth Capital Partners, LLC are acting as representatives (the “Representatives”), 2,730,000 shares of common stock, $0.0001 par value per share (“Common Stock”) of the Issuer (said shares to be issued and sold by the Issuer being hereinafter called the “Underwritten Securities”). The Issuer also proposes to grant to the Underwriters an option to purchase up to 409,500 additional shares of Common Stock to cover over-allotments, if any (the “Option Securities;” the Option Securities, together with the Underwritten Securities, hereinafter called the “Securities”). The offering and sale of the Securities contemplated by this Agreement is referred to herein as the “Offering.”
Eyenovia, Inc. [·] Shares Common Stock ($0.0001 par value) Underwriting AgreementUnderwriting Agreement • January 9th, 2018 • Eyenovia, Inc. • Pharmaceutical preparations • New York
Eyenovia, Inc., a corporation organized under the laws of Delaware (the “Issuer”), proposes to issue and sell to the several underwriters named in Schedule I hereto (the “Underwriters”), for whom Ladenburg Thalmann & Co. Inc. is acting as representative (the “Representative”), [·] shares of common stock, $0.0001 par value per share (“Common Stock”) of the Issuer (said shares to be issued and sold by the Issuer being hereinafter called the “Underwritten Securities”). The Issuer also proposes to grant to the Underwriters an option to purchase up to [·] additional shares of Common Stock to cover over-allotments, if any (the “Option Securities;” the Option Securities, together with the Underwritten Securities, hereinafter called the “Securities”). The offering and sale of the Securities contemplated by this Agreement is referred to herein as the “Offering.”
Arsanis, Inc. [●] Shares Common Stock ($0.001 par value) Underwriting AgreementUnderwriting Agreement • November 6th, 2017 • Arsanis, Inc. • Biological products, (no disgnostic substances) • New York
Arsanis, Inc., a corporation organized under the laws of Delaware (the “Issuer”), proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”), for whom Citigroup Global Markets Inc., Cowen and Company, LLC and Piper Jaffray & Co. (the “Representatives”) are acting as representatives, [●] shares of common stock, $0.001 par value per share (“Common Stock”) of the Issuer (said shares to be issued and sold by the Issuer being hereinafter called the “Underwritten Securities”). The Issuer also proposes to grant to the Underwriters an option to purchase up to [●] additional shares of Common Stock to cover over-allotments, if any (the “Option Securities;” the Option Securities, together with the Underwritten Securities, hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule I other than you, the term Representatives as used herein shall
Kadmon Holdings, Inc. 18,500,000 Shares of Common Stock ($0.001 par value) 18,500,000 Warrants to Purchase 7,400,000 Shares of Common Stock Underwriting AgreementUnderwriting Agreement • September 28th, 2017 • Kadmon Holdings, Inc. • Pharmaceutical preparations • New York
Kadmon Holdings, Inc., a Delaware corporation (the “Issuer”), proposes to issue and sell to the several underwriters named in Schedule I hereto (the “Underwriters”), for whom Piper Jaffray & Co. (“Piper”) and Jefferies LLC (“Jefferies”, and together with Piper, the “Representatives”) are acting as representatives, (i) 18,500,000 shares (the “Firm Shares”) of common stock, $0.001 par value (“Common Stock”), of the Issuer and (ii) 18,500,000 warrants to purchase an aggregate of 7,400,000 shares of Common Stock (the “Firm Warrants”) of the Issuer. The Issuer also proposes to grant to the Underwriters an option to purchase up to (i) 2,775,000 additional shares of Common Stock (the “Option Shares” and together with the Firm Shares, the “Shares”) and/or (ii) 2,775,000 additional warrants to purchase up to an additional 1,110,000 shares of Common Stock (the “Option Warrants” and together with the Firm Warrants, the “Warrants”). Each Share is being sold together with a Warrant to purchase 0.4
Krystal Biotech, Inc. [●] Shares Common Stock ($0.00001 par value) Underwriting AgreementUnderwriting Agreement • September 14th, 2017 • Krystal Biotech, Inc. • Biological products, (no disgnostic substances) • New York
Krystal Biotech, Inc., a corporation organized under the laws of Delaware (the “Issuer”), proposes to issue and sell to the several underwriters named in Schedule I hereto (the “Underwriters”), for whom Ladenburg Thalmann & Co. Inc. is acting as representative (the “Representative”), [●] shares of common stock, $0.00001 par value per share (“Common Stock”) of the Issuer (said shares to be issued and sold by the Issuer being hereinafter called the “Underwritten Securities”). The Issuer also proposes to grant to the Underwriters an option to purchase up to [●] additional shares of Common Stock to cover over-allotments, if any (the “Option Securities;” the Option Securities, together with the Underwritten Securities, hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule I other than you, the term Representative as used herein shall mean you, as Underwriter, and the terms Representative and Underwriter shall mean either the singular or
Myovant Sciences Ltd. [●] Shares 1 Common Shares ($0.00001 par value) Underwriting AgreementUnderwriting Agreement • October 17th, 2016 • Myovant Sciences Ltd. • Pharmaceutical preparations • New York
Myovant Sciences Ltd., a company incorporated and organized under the laws of Bermuda (the “Issuer”), proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as Representatives, [●] common shares, $0.00001 par value per common share (“Common Shares”), of the Issuer (said Common Shares to be issued and sold by the Issuer being hereinafter called the “Underwritten Securities”). The Issuer also proposes to grant to the Underwriters an option to purchase up to [●] additional Common Shares to cover over-allotments, if any (the “Option Securities;” the Option Securities, together with the Underwritten Securities, hereinafter called the “Securities”).
Common Stock ($0.001 par value) Underwriting AgreementUnderwriting Agreement • July 14th, 2016 • Kadmon Holdings, LLC • Pharmaceutical preparations • New York
Kura Oncology, Inc. [•] Shares1 Common Stock ($0.0001 par value) Underwriting AgreementUnderwriting Agreement • October 28th, 2015 • Kura Oncology, Inc. • Pharmaceutical preparations • New York
Kura Oncology, Inc., a Delaware corporation (the “Issuer”), proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, [•] shares of common stock, $0.0001 par value (“Common Stock”) of the Issuer (said shares to be issued and sold by the Issuer being hereinafter called the “Underwritten Securities”). The Issuer also proposes to grant to the Underwriters an option to purchase up to [•] additional shares of Common Stock to cover over-allotments, if any (the “Option Securities;” the Option Securities, together with the Underwritten Securities, hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule I other than you, the term Representatives as used herein shall mean you, as Underwriters, and the terms Representatives and Underwriters shall mean either the singular or plural as the context requires.
